Menu
Search
|

Menu

Close
X

Proteostasis Therapeutics Inc PTI.OQ (NASDAQ Stock Exchange Global Market)

6.14 USD
-0.09 (-1.44%)
As of 8:59 PM GMT
chart
Previous Close 6.23
Open 6.18
Volume 221,202
3m Avg Volume 387,180
Today’s High 6.48
Today’s Low 6.06
52 Week High 10.38
52 Week Low 1.66
Shares Outstanding (mil) 25.10
Market Capitalization (mil) 55.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
5
FY16
8
FY15
4
EPS (USD)
FY18
-1.252
FY17
-2.344
FY16
-2.256
FY15
-1.220
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
6.98
5.69
Price to Book (MRQ)
vs sector
1.08
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-123.49
15.05
Return on Equity (TTM)
vs sector
-127.78
16.62

EXECUTIVE LEADERSHIP

M. James Barrett
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Meenu Chhabra
President, Chief Executive Officer, Director, Since 2014
Salary: $450,138.00
Bonus: $232,500.00
Marija Zecevic
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Po-Shun Lee
Executive Vice President, Chief Medical Officer, Since
Salary: $334,892.00
Bonus: $119,000.00
Benito Munoz
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

80 Guest St Fl 5
BOSTON   MA   02135-2028

Phone: +1617.2250096

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

SPONSORED STORIES